Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) is dated March 4, 2024. The report addresses a corporate governance event regarding the company's listing status on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On March 4, 2024, the company received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)). This closes a matter initiated on October 19, 2023, when the company was notified that its common stock had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies. The document solely confirms the closure of the minimum bid price compliance issue.
Key Facts for Investor Verification
- Verify the current trading price of GOSS to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the date of the Nasdaq compliance letter (March 4, 2024) against the company's public announcements.
- Note that the previous non-compliance period began after October 19, 2023.